Loading...
Docoh

Opiant Pharmaceuticals (OPNT)

News

From Benzinga Pro
110 Biggest Movers From Friday
16 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Stocks That Hit 52-Week Lows On Friday
13 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 153 companies set new 52-week lows.
OPNT: Positive Results for Pharmacodynamic Trial of OPNT003…
12 May 22
Small Cap
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT
99 Biggest Movers From Yesterday
12 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 May 22
Intraday Update, Markets, Movers
Opiant Pharmaceuticals Q1 EPS $(2.43) Down From $(0.66) YoY, Sales $4.47M Miss $5.90M Estimate
10 May 22
Earnings, News
Opiant Pharmaceuticals (NASDAQ:OPNT) reported quarterly losses of $(2.43) per share. This is a 268.18 percent decrease over losses of $(0.66) per share from the same period last year. The company reported quarterly
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May 22
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For May 10, 2022
10 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
A Preview Of Opiant Pharmaceuticals's Earnings
9 May 22
Earnings
Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Opiant Pharmaceuticals will report an earnings per share (EPS) of $-0.91.
70 Biggest Movers From Friday
2 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
12 Health Care Stocks Moving In Friday's Intraday Session
29 Apr 22
Intraday Update, Markets, Movers
48 Stocks Moving In Friday's Mid-Day Session
29 Apr 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
Opiant Pharmaceuticals Says To 'Disregard' Prior News Of $225M Licensing Agreement; Says Intial Release 'Contains Incorrect Information
29 Apr 22
News, Contracts, FDA
We are advised by Opiant Pharmaceuticals that journalists and other readers should disregard the news release, Opiant Pharmaceuticals and Hikma announce exclusive $225 million commercialisation and license agreement for
Opiant Pharmaceuticals And Hikma Earlier Announced Exclusive $225M Commercialization And License Agreement For OPNT003, Nasal Nalmefene, In Europe And UK
29 Apr 22
News, Contracts, FDA
https://www.yahoo.com/now/opiant-pharmaceuticals-hikma-announce-exclusive-131500021.html
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
28 Apr 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Guidance, Health Care, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Opiant Pharmaceuticals Shares Are Soaring Today
28 Apr 22
Biotech, News, Health Care, Movers, Trading Ideas, General
President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters
21 Apr 22
Biotech, Government, News, Health Care, Legal, General
OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…
17 Mar 22
Small Cap
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT
Looking Into Opiant Pharmaceuticals's Return On Capital Employed
17 Mar 22
Earnings
According to Benzinga Pro, during Q4, Opiant Pharmaceuticals (NASDAQ:OPNT) earned $752.33 thousand, a 77.98% increase from the preceding quarter. Opiant Pharmaceuticals's sales decreased to $13.80 million, a 15.54% change since Q3.
Opiant Pharmaceuticals: Q4 Earnings Insights
15 Mar 22
Earnings
Opiant Pharmaceuticals (NASDAQ:OPNT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Press releases

From Benzinga Pro
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
20 May 22
News, Press Releases
SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
10 May 22
Earnings, News, Press Releases
SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today
Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release
29 Apr 22
Press Releases
SANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ:OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with
Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone
27 Apr 22
Health Care, Press Releases
Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioidOPNT003 met the primary endpoint of non-inferiority,
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
15 Mar 22
Earnings, Press Releases
SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today
Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference
10 Mar 22
News, Health Care, Press Releases
SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
7 Mar 22
News, Press Releases
SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced